Current treatment for nocardia infections

Bibliography

• McTaggart LR, Richardson SE, Witkowska M, et al. Phylogeny and identification of Nocardia species on the basis of multilocus sequence analysis. J Clin Microbiol 2010;48:4525-33
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006;19:259-82
   PubMed Web of Science ®Google Scholar
• Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012;87:403-7
   PubMed Web of Science ®Google Scholar
• Schlaberg R, Huard RC, Della-Latta P. Nocardia cyriacigeorgica, an emerging pathogen in the United States. J Clin Microbiol 2008;46:265-73
   PubMed Web of Science ®Google Scholar
• Minero MV, Marín M, Cercenado E, et al. Nocardiosis at the turn of the century. Medicine 2009;88:250-61
   PubMed Web of Science ®Google Scholar
• Hui CH, Au VW, Rowland K, et al. Pulmonary nocardiosis re-visited: experience of 35 patients at diagnosis. Respir Med 2003;97:709-17
   PubMed Web of Science ®Google Scholar
• Smego RA Jr, Foglia G. Actinomycosis. Clin Infect Dis 1998;26:1255-61; quiz 62-3
   PubMed Web of Science ®Google Scholar
• Lerner PI. Nocardiosis. Clin Infect Dis 1996;22:891-903; quiz 4-5
   PubMed Web of Science ®Google Scholar
• Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev 1994;7:213-64
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Welsh E, et al. Actinomycetoma and advances in its treatment. Clin Dermatol 2012;30:372-81
   PubMed Web of Science ®Google Scholar
• Isik K, Goodfellow M. Differentiation of nocardia species by PCR-randomly amplified polymorphic DNA fingerprinting. Syst Appl Microbiol 2002;25:60-7
   PubMed Web of Science ®Google Scholar
• Almaguer-Chavez JA, Welsh O, Lozano-Garza HG, et al. Decrease of virulence for BALB/c mice produced by continuous subculturing of Nocardia brasiliensis. BMC Infect Dis 2011;11:290
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Yamashita A, Mikami Y, et al. The complete genomic sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci USA 2004;101:14925-30
   PubMed Web of Science ®Google Scholar
• Sanchez-Herrera K, Sandoval H, Couble A, et al. Phenotypic and genotypic evaluation of 18 Nocardia isolates from human clinical samples in Mexico. J Mycol Med 2012;22:1-7
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Ortiz-Lopez R, Elizondo-Gonzalez R, et al. Complete genome sequence analysis of nocardia brasiliensis HUJEG-1 reveals a saprobic lifestyle and the genes needed for human pathogenesis. PLoS One 2013;8:e65425
   PubMed Web of Science ®Google Scholar
• Iannotti CA, Hall GS, Procop GW, et al. Solitary Nocardia farcinica brain abscess in an immunocompetent adult mimicking metastatic brain tumor: rapid diagnosis by pyrosequencing and successful treatment. Surg Neurol 2009;72:74-9; discussion 9
   PubMedGoogle Scholar
• Boiron P, Provost F. Use of partially purified 54-kilodalton antigen for diagnosis of nocardiosis by Western blot (immunoblot) assay. J Clin Microbiol 1990;28:328-31
   PubMed Web of Science ®Google Scholar
• Salinas-Carmona MC, Welsh O, Casillas SM. Enzyme-linked immunosorbent assay for serological diagnosis of Nocardia brasiliensis and clinical correlation with mycetoma infections. J Clin Microbiol 1993;31:2901-6
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Salinas-Carmona MC, Waksman N, et al. Host defenses in subcutaneous mycoses. Clin Dermatol 2012;30:382-8
   PubMed Web of Science ®Google Scholar
• Garcia M. Sulfonas en el tratamiento del micetoma. Estudio de un caso. Prensa Medica Mexicana 1950;15:262-6
   PubMedGoogle Scholar
• González-Ochoa A, Shiels J, Vázquez P. Acción de la 4,4 diamino-difenil-sulfona frente a Nocardia brasiliensis. Gac Med Mex 1952;82:345-53
   PubMedGoogle Scholar
• Latapi F, Lavalle P. editors. Emploi des sulfones et de L´isoniazide dans le traitment des mycetomes. VIII Congres International de Botanique; Paris, France; 1954
   Google Scholar
• Wallace RJ Jr, Steele LC, Sumter G, et al. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988;32:1776-9
   PubMed Web of Science ®Google Scholar
• Larruskain J, Idigoras P, Marimon JM, et al. Susceptibility of 186 Nocardia sp. isolates to 20 antimicrobial agents. Antimicrob Agents Chemother 2011;55:2995-8
   PubMed Web of Science ®Google Scholar
• Lai CC, Liu WL, Ko WC, et al. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species. Antimicrob Agents Chemother 2011;55:2084-91
   PubMed Web of Science ®Google Scholar
• Hamid ME, Maldonado L, Sharaf Eldin GS, et al. Nocardia africana sp. nov., a new pathogen isolated from patients with pulmonary infections. J Clin Microbiol 2001;39:625-30
   PubMed Web of Science ®Google Scholar
• Ezeoke I, Klenk HP, Potter G, et al. Nocardia amikacinitolerans sp. nov., an amikacin-resistant human pathogen. Int J Syst Evol Microbiol 2013;63:1056-61
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ochoa A. Experimental production of mycetoma by Nocardia braziliensis in the mouse. Gac Med Mex 1969;99:773-81
   PubMedGoogle Scholar
• Libecco JA, Powell KR. Trimethoprim/sulfamethoxazole: clinical update. Pediatr Rev 2004;25:375-80
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010;38:89-97
   PubMed Web of Science ®Google Scholar
• Corti ME, Villafane-Fioti MF. Nocardiosis: a review. Int J Infect Dis 2003;7:243-50
   PubMedGoogle Scholar
• Uhde KB, Pathak S, McCullum I Jr, et al. Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis 2010;51:1445-8
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Biehle J, Conville PS, et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol 2012;50:670-2
   PubMed Web of Science ®Google Scholar
• Tremblay J, Thibert L, Alarie I, et al. Nocardiosis in Quebec, Canada, 1988-2008. Clin Microbiol Infect 2011;17:690-6
   PubMed Web of Science ®Google Scholar
• Conville PS, Brown-Elliott BA, Wallace RJ Jr, et al. Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species. J Clin Microbiol 2012;50:1270-80
   PubMed Web of Science ®Google Scholar
• Shakil S, Khan R, Zarrilli R, et al. Aminoglycosides versus bacteria–a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci 2008;15:5-14
   PubMed Web of Science ®Google Scholar
• Gomez-Flores A, Welsh O, Said-Fernandez S, et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48:832-7
   PubMed Web of Science ®Google Scholar
• Matulionyte R, Rohner P, Uckay I, et al. Secular trends of nocardia infection over 15 years in a tertiary care hospital. J Clin Pathol 2004;57:807-12
   PubMed Web of Science ®Google Scholar
• Welsh O, Lopez R. Micetomas con diseminación pulmonar. Med Cutan Ibero Lat Am 1985;13:517-23
   PubMedGoogle Scholar
• Welsh O, Sauceda E, Gonzalez J, et al. Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. J Am Acad Dermatol 1987;17:443-8
   PubMed Web of Science ®Google Scholar
• Nelson ML, Levy SB. The history of the tetracyclines. Ann NY Acad Sci 2011;1241:17-32
   PubMed Web of Science ®Google Scholar
• Lewis KE, Ebden P, Wooster SL, et al. Multi-system Infection with Nocardia farcinica-therapy with linezolid and minocycline. J Infect 2003;46:199-202
   PubMed Web of Science ®Google Scholar
• Ogawa T, Kasahara K, Yonekawa S, et al. Nocardia beijingensis pulmonary infection successfully treated with intravenous beta-lactam antibiotics and oral minocycline. J Infect Chemother 2011;17:706-9
   PubMed Web of Science ®Google Scholar
• Geria AN, Tajirian AL, Kihiczak G, et al. Minocycline-induced skin pigmentation: an update. Acta Dermatovenerol Croat 2009;17:123-6
   PubMed Web of Science ®Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-14
   PubMed Web of Science ®Google Scholar
• Cercenado E, Marin M, Sanchez-Martinez M, et al. In vitro activities of tigecycline and eight other antimicrobials against different Nocardia species identified by molecular methods. Antimicrob Agents Chemother 2007;51:1102-4
   PubMed Web of Science ®Google Scholar
• Lai C-C, Tan C-K, Lin SH, et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 2009;64:73-8
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
   PubMed Web of Science ®Google Scholar
• Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110-16
   PubMed Web of Science ®Google Scholar
• Petri WA Jr. Penicillins, cephalosporins and other beta-lactam antibiotics. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's the pharmacological basis of therapeutics. McGraw Hill Professional; New York: 2010. p. 1477-504
   Google Scholar
• Gomez A, Saul A, Bonifaz A, et al. Amoxicillin and clavulanic acid in the treatment of actinomycetoma. Int J Dermatol 1993;32:218-20
   PubMed Web of Science ®Google Scholar
• Bonifaz A, Flores P, Saúl A, et al. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin–clavulanate. Br J Dermatol 2007;156:308-11
   PubMed Web of Science ®Google Scholar
• Clissold SP, Todd PA, Campoli-Richards DM. Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987;33:183-241
   PubMed Web of Science ®Google Scholar
• Ameen M, Arenas R, Vasquez del Mercado E, et al. Efficacy of imipenem therapy for Nocardia actinomycetomas refractory to sulfonamides. J Am Acad Dermatol 2010;62:239-46
   PubMed Web of Science ®Google Scholar
• Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36(Suppl A):207-23
   PubMed Web of Science ®Google Scholar
• Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. DICP 1990;24:467-9
   PubMedGoogle Scholar
• Zhanel GG, Simor AE, Vercaigne L, et al. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis 1998;9:215-28
   PubMedGoogle Scholar
• McEvoy GK. AHFS drug information 2006. American Society of Health-System Pharmacists, Inc; Bethesda, MD: 2006
   Google Scholar
• Maheswaran AM. Mosby's drug consult 2006. Elsevier Mosby; St. Louis: 2005
   Google Scholar
• Tuo MH, Tsai YH, Tseng HK, et al. Clinical experiences of pulmonary and bloodstream nocardiosis in two tertiary care hospitals in northern Taiwan, 2000-2004. J Microbiol Immunol Infect 2008;41:130-6
   PubMedGoogle Scholar
• Nishida R, Mori Y, Iwasaki H, et al. Pulmonary nocardiosis developed in a hematopoietic stem cell transplant recipient with bronchiolitis obliterans. Intern Med 2010;49:1441-4
   PubMed Web of Science ®Google Scholar
• Yazawa K, Mikami Y, Ohashi S, et al. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J Antimicrob Chemother 1992;29:169-72
   PubMed Web of Science ®Google Scholar
• Chacon-Moreno BE, Welsh O, Cavazos-Rocha N, et al. Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice. Antimicrob Agents Chemother 2009;53:295-7
   PubMed Web of Science ®Google Scholar
• Fihman V, Bercot B, Mateo J, et al. First successful treatment of Nocardia farcinica brain abscess with moxifloxacin. J Infect 2006;52:e99-102
   PubMedGoogle Scholar
• Kandasamy J, Iqbal HJ, Cooke RP, et al. Primary Nocardia farcinica brain abscess with secondary meningitis and ventriculitis in an immunocompetent patient, successfully treated with moxifloxacin. Acta Neurochir (Wien) 2008;150:505-6
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009;32:359-78
   PubMed Web of Science ®Google Scholar
• Sensi P. History of the development of rifampin. Rev Infect Dis 1983;5(Suppl 3):S402-6
   PubMedGoogle Scholar
• Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010;23:14-34
   PubMed Web of Science ®Google Scholar
• Lerner PI, Baum GL. Antimicrobial susceptibility of Nocardia species. Antimicrob Agents Chemother 1973;4:85-93
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yazawa K, Dabbs ER, et al. Different rifampicin inactivation mechanisms in Nocardia and related taxa. Microbiol Immunol 1996;40:1-4
   PubMed Web of Science ®Google Scholar
• Yazawa K, Mikami Y, Maeda A, et al. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum. J Antimicrob Chemother 1994;33:1127-35
   PubMed Web of Science ®Google Scholar
• Yazawa K, Mikami Y, Maeda A, et al. Inactivation of rifampin by Nocardia brasiliensis. Antimicrob Agents Chemother 1993;37:1313-17
   PubMed Web of Science ®Google Scholar
• Damle DK, Mahajan PM, Pradhan SN, et al. Modified Welsh regimen: a promising therapy for actinomycetoma. J Drugs Dermatol 2008;7:853-6
   PubMedGoogle Scholar
• Praveen Kumar S, Sumathy TK, Shyam Prasad AL, et al. An unusual presentation of primary cutaneous nocardiosis at a rare site: succesful treatment with a modified Welsh regimen. Dermatol Online J 2011;17:1
   PubMedGoogle Scholar
• Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27; discussion 28
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann NY Acad Sci 2011;1241:48-70
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Gomez-Flores A, Escalante-Fuentes WG, et al. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis. Antimicrob Agents Chemother 2001;45:3629-30
   PubMed Web of Science ®Google Scholar
• Jodlowski TZ, Melnychuk I, Conry J. Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother 2007;41:1694-9
   PubMed Web of Science ®Google Scholar
• Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 2003;36:313-18
   PubMed Web of Science ®Google Scholar
• Shen T, Wu L, Geng L, et al. Successful treatment of pulmonary Nocardia farcinica infection with linezolid: case report and literature review. Braz J Infect Dis 2011;15:486-9
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Gonzalez E, Rendon A, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 2006;50:3170-2
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Espinoza-Gonzalez NA, Welsh O, et al. Activity of novel oxazolidinones against Nocardia brasiliensis growing within THP-1 macrophages. J Antimicrob Chemother 2009;64:1013-17
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309:559-69
   PubMed Web of Science ®Google Scholar
• Vera-Cabrera L, Campos-Rivera MP, Gonzalez-Martinez NA, et al. In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis. Antimicrob Agents Chemother 2012;56:3984-5
   PubMed Web of Science ®Google Scholar
• Serrano JA, Beaman B, Mejia MA, et al. Histological and microbiological aspects of actinomycetoma cases in Venezuela. Rev Inst Med Trop Sao Paulo 1988;30:297-304
   PubMed Web of Science ®Google Scholar
• Zein HA, Fahal AH, Mahgoub el S, et al. Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan. Trans R Soc Trop Med Hyg 2012;106:639-44
   PubMed Web of Science ®Google Scholar
• Kresch-Tronik NS, Carrillo-Casas EM, Arenas R, et al. Nocardia harenae, an uncommon causative organism of mycetoma: report on two patients. J Med Microbiol 2012;61:1153-5
   PubMed Web of Science ®Google Scholar
• Kresch-Tronik NS, Carrillo-Casas EM, Arenas R, et al. First case of mycetoma associated with Nocardia takedensis. J Dermatol 2013;40:135-6
   PubMed Web of Science ®Google Scholar
• Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003;41:4497-501
   PubMed Web of Science ®Google Scholar
• Trevino-Villarreal JH, Vera-Cabrera L, Valero-Guillen PL, et al. Nocardia brasiliensis cell wall lipids modulate macrophage and dendritic responses that favor development of experimental actinomycetoma in BALB/c mice. Infect Immun 2012;80:3587-601
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Eramo SL, Rolesi R, et al. Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 2012;32:103-10
   PubMed Web of Science ®Google Scholar